Literature DB >> 12074832

Changes of plasma free choline and choline-containing compounds' concentrations and choline loss during hemodialysis in ESRD patients.

Yesim Ozarda Ilcol1, Kamil Dilek, Mustafa Yurtkuran, Ismail H Ulus.   

Abstract

OBJECTIVES: This study was undertaken to determine the changes in plasma free choline and choline-containing compounds in end stage renal disease (ESRD) and to determine if they were lost into the dialysate during hemodialysis. DESIGN AND METHODS: Plasma and dialysate free choline, phosphocholine and phospholipid-, phosphatidylcholine-, sphingomyelin-bound choline were measured before, during and after hemodialysis.
RESULTS: Plasma free and bound choline concentrations (mean +/- standard error of the mean) were 12.9 +/- 0.6 and 2697 +/- 57 microM or 37.3 +/- 0.9 and 2792 +/- 98 microM in controls or in ESRD patients, respectively. Free choline concentrations were correlated (r = 0.598; p < 0.001) with the time the patients were subjected to hemodialysis. Plasma free choline and phosphocholine concentrations are decreased by a total of -8.1 +/- 0.6 micromol/L and -88 +/- 8 micromol/L, respectively; phospholipid-, phosphatidylcholine- and sphingomyelin-bound choline are increased, during hemodialysis. Patients lost about 350 micromoles of choline into the dialysate during hemodialysis.
CONCLUSION: Plasma free choline concentrations are elevated in ESRD, and a considerable amount of choline is lost into the hemodialysate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074832     DOI: 10.1016/s0009-9120(02)00298-9

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  7 in total

1.  Shear stress induces cell apoptosis via a c-Src-phospholipase D-mTOR signaling pathway in cultured podocytes.

Authors:  Chunfa Huang; Leslie A Bruggeman; Lindsey M Hydo; R Tyler Miller
Journal:  Exp Cell Res       Date:  2012-03-26       Impact factor: 3.905

Review 2.  Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery.

Authors:  Maria Cappuccilli; Camilla Bergamini; Floriana A Giacomelli; Giuseppe Cianciolo; Gabriele Donati; Diletta Conte; Teresa Natali; Gaetano La Manna; Irene Capelli
Journal:  Nutrients       Date:  2020-04-27       Impact factor: 5.717

3.  Metabolomics Evaluation of Patients With Stage 5 Chronic Kidney Disease Before Dialysis, Maintenance Hemodialysis, and Peritoneal Dialysis.

Authors:  Sang Zhu; Feng Zhang; Ai-Wen Shen; Bo Sun; Tian-Yi Xia; Wan-Sheng Chen; Xia Tao; Sheng-Qiang Yu
Journal:  Front Physiol       Date:  2021-01-20       Impact factor: 4.566

Review 4.  The pathophysiology of leg cramping during dialysis and the use of carnitine in its treatment.

Authors:  Akira Takahashi
Journal:  Physiol Rep       Date:  2021-11

5.  Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism.

Authors:  Ying-Yong Zhao; Ya-Long Feng; Xu Bai; Xiao-Jie Tan; Rui-Chao Lin; Qibing Mei
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

6.  Canonical and Novel Non-Canonical Cholinergic Agonists Inhibit ATP-Induced Release of Monocytic Interleukin-1β via Different Combinations of Nicotinic Acetylcholine Receptor Subunits α7, α9 and α10.

Authors:  Anna Zakrzewicz; Katrin Richter; Alisa Agné; Sigrid Wilker; Kathrin Siebers; Bijan Fink; Gabriela Krasteva-Christ; Mike Althaus; Winfried Padberg; Arik J Hone; J Michael McIntosh; Veronika Grau
Journal:  Front Cell Neurosci       Date:  2017-07-05       Impact factor: 5.505

7.  Measurement of plasma choline in acute coronary syndrome: importance of suitable sampling conditions for this assay.

Authors:  Ryunosuke Ohkawa; Makoto Kurano; Noboru Sakai; Tatsuya Kishimoto; Takahiro Nojiri; Koji Igarashi; Shigemi Hosogaya; Yukio Ozaki; Tomotaka Dohi; Katsumi Miyauchi; Hiroyuki Daida; Junken Aoki; Shigeo Okubo; Hitoshi Ikeda; Minoru Tozuka; Yutaka Yatomi
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.